Ensysce Biosciences appoints Lee Rauch to board of directors

Ensysce Biosciences, Inc.

Lee Rauch appointed as Class I director effective Feb 8, 2022; term expires at 2022 annual meeting.
Rauch will serve on Compensation Committee; granted option for 20,000 shares at $1.70 per share.
Receives annual cash compensation of $7,500, prorated for service through the 2022 annual meeting.
Rauch is a 40-year industry veteran, former CEO of Viridian Therapeutics and founding member of McKinsey's pharma practice.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Lee Rauch

Director

ENSC · Ensysce Biosciences, Inc.

Effective: 2022-02-08
Filed: February 8, 2022, 6:59 PM ET

On February 8, 2022, the Board of Ensysce Biosciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Lee Rauch to its Board of Directors (“Board”), effective immediately (the “New Director”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Lee Rauch was appointed as Director at Ensysce Biosciences, Inc..

Action: appointed
Role: Director

Exact text from the filing

On February 8, 2022, the Board of Ensysce Biosciences, Inc. (the “Company”), upon the recommendation of its Nominating and Corporate Governance Committee, appointed Lee Rauch to its Board of Directors (“Board”), effective immediately (the “New Director”).

View on SEC.gov

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-003481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.